All In Biotech

Drug Trial Radar · NCT01371838

A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 848 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

848

Actual

Start

Dec 2011

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
Jun 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 150 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.

Conditions

  • Community-Acquired Bacterial Pneumonia
  • Lung Infection of Individual Not Recently Hospitalized

Interventions

  • CeftarolineDrug

    Two consecutive infusions q12h for 5 to 7 days

  • CeftriaxoneDrug

    One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE PopulationTime frame: 7-20 days after last dose of study drug

Locations

43 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Haikou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Jiangyin, China

  • Research Site

    Nanchang, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenzhen, China

  • Research Site

    Shijiazhuang, China

  • Research Site

    Wuxi, China

  • Research Site

    Bangalore, India

  • Research Site

    Calicut, India

  • Research Site

    Goa, India

  • Research Site

    Hyderabad, India

  • Research Site

    Jaipur, India

  • Research Site

    Lucknow, India

  • Research Site

    Ludhiana, India

  • Research Site

    Mysore, India

  • Research Site

    New Delhi, India

  • Research Site

    Trivandrum, India

  • Research Site

    Varanasi, India

  • Research Site

    Vellore, India

  • Research Site

    Anyang-si, South Korea

  • Research Site

    Bucheon-si, South Korea

  • Research Site

    Cheonan-si, South Korea

  • Research Site

    Chuncheon, South Korea

  • Research Site

    Daegu, South Korea

  • Research Site

    Daejeon, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

  • Research Site

    Wŏnju, South Korea

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Keelung, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Can Tho, Vietnam

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.